

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.
and MYLAN LABORATORIES LIMITED,
Petitioner,

v.

UCB PHARMA GMBH,
Patent Owner.

Case IPR2016-00512
Patent 7,384,980 B2

Before KRISTINA M. KALAN, ROBERT A. POLLOCK, and
MICHELLE N. ANKENBRAND, *Administrative Patent Judges*.

KALAN, *Administrative Patent Judge*.

FINAL WRITTEN DECISION

Finding Claims 1–16 Not Unpatentable
35 U.S.C. § 318(a) and 37 C.F.R. § 42.73

Dismissing as Moot Patent Owner's Motion to Exclude
37 C.F.R. § 42.64(c)

Granting Joint Motion to Seal and Entering Default Protective Order
37 C.F.R. § 42.54

I. INTRODUCTION

Mylan Pharmaceuticals Inc. and Mylan Laboratories Limited (“Mylan” or “Petitioner”) filed a Corrected Petition requesting an *inter partes* review of claims 1–16 of U.S. Patent No. 7,384,980 B2 (Ex. 1001, “the ‘980 patent”). Paper 5 (“Pet.”). UCB Pharma GmbH, (“UCB” or “Patent Owner”) filed a Preliminary Response to the Petition. Paper 9 (“Prelim. Resp.”). We instituted an *inter partes* review of claims 1–16 on certain grounds of unpatentability alleged in the Petition. Paper 12 (“Dec.”). After institution of trial, Patent Owner filed a Patent Owner Response (Paper 17, “PO Resp.”) and Petitioner filed a Reply (Paper 21, “Reply”). An oral hearing was held on April 5, 2017. A transcript of the hearing has been entered into the record. Paper 36 (“Tr.”).

The Board has jurisdiction under 35 U.S.C. § 6. In this Final Written Decision, issued pursuant to 35 U.S.C. § 318(a) and 37 C.F.R. § 42.73, we determine that Petitioner has not shown by a preponderance of the evidence that the claims for which we instituted trial, namely, claims 1–16, are unpatentable under 35 U.S.C. § 103.

II. BACKGROUND

A. Related Matters

Patent Owner asserts that

UCB and Pfizer Inc. (“Pfizer”), the exclusive licensee of the ‘980 patent, have sued Mylan Pharmaceuticals Inc. for infringement of the ‘980 patent in the following actions: *Pfizer, Inc. and UCB Pharma GMBH v. Mylan Pharmaceuticals, Inc.*, No. 1:15-cv-00079-GMS (D. Del.) and *Pfizer Inc. and UCB Pharma GMBH v. Mylan Pharmaceuticals Inc.*, Case No. 1:15-cv-00013-IMK (N.D.W.Va.).

Paper 8, 2; *see* Pet. 1–2 (noting that Pfizer is the NDA holder).

IPR2016-00512
Patent 7,384,980 B2

The '980 patent is also at issue in *Pfizer, Inc. v. Sandoz, Inc.*, No. 1:13-cv-01110-GMS (D. Del.),¹ and in the now-dismissed action, *Pfizer, Inc. v. Dr. Reddy's Laboratories, Ltd.*, No. 1:15-cv-01067 (GMS) (D. Del.).
Paper 8, 2.

In addition to the case before us, we instituted *inter partes* review in the following matters involving patents with substantially the same specification as the '980 patent at issue here:

Case No. IPR2016-00514 (U.S. Patent No. 7,855,230 B2) (Paper 12);
Case No. IPR2016-00516 (U.S. Patent No. 8,338,478 B2) (Paper 12); and
Case No. IPR2016-00517 (U.S. Patent No. 7,985,772 B2) (Paper 12).

We also instituted *inter partes* review in IPR2016-00510 (U.S. Patent No. 6,858,650 B1) (Paper 12), a matter involving another UCB patent generally directed, as are the above patents, to 3,3-diphenylpropylamine compounds.²

Patent Owner updated its mandatory notices on February 16, 2017, to reflect that Case No. 1:15-cv-00079-GMS concluded with a general verdict in favor of Plaintiffs, and that UCB Pharma GmbH and Pfizer Inc., the exclusive licensee of the asserted patents, filed suit against Torrent

¹ Patent Owner provides, as Exhibit 2001, the District Court's Memorandum finding that the defendants in that proceeding "failed to present a prima facie case that the asserted claims of the patents-in-suit are invalid as obvious." Ex. 2001, 19. Although the district court reached this determination on a different record and applied different standards, the arguments and references applied overlap with those before us. *See* Ex. 2001. Accordingly, while we are not bound to these findings, we find the court's analysis informative.

² Petitioners Alembic Pharmaceuticals Limited from IPR2016-01596, Torrent Pharmaceuticals Limited from IPR2016-01636, and Amerigen Pharmaceuticals Limited from IPR2016-01665 were joined as Petitioners to IPR2016-00510. IPR 2016-00510, Papers 24–26.

IPR2016-00512
Patent 7,384,980 B2

Pharmaceuticals Limited and Torrent Pharma Incorporated for infringement of the asserted patents in *Pfizer, Inc. v. Torrent Pharm. Ltd.*, No. 1:17-cv-00112-GMS (D. Del.). Paper 26, 2.

B. The '980 Patent

The '980 patent, entitled “Derivatives of 3,3-Diphenylpropylamines,” issued on June 10, 2008, with Claus Meese and Bengt Sparf as the listed co-inventors. Ex. 1001. The '980 patent is generally directed to “derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs.” *Id.* at Abstract.


The Specification discloses that “normal urinary bladder contractions are mediated mainly through cholinergic muscarinic receptor stimulation.” *Id.* at 1:16–17. Because the same muscarinic receptors appear to also mediate contractions of the overactive bladder and associated symptoms of urinary frequency, frequency urge, and urge incontinence, antimuscarinic drugs have been proposed for the treatment of bladder overactivity. *Id.* at 1:20–23. “Among the antimuscarinic drugs available on the market, oxybutynin is currently regarded as the gold standard for pharmacological treatment of urge incontinence and other symptoms related to bladder overactivity” but its usefulness is limited by antimuscarinic side effects, most particularly, dry mouth. *Id.* at 1:24–31.

“Tolterodine is a new, potent and competitive, muscarinic receptor antagonist intended for the treatment of urinary urge incontinence and [bladder wall muscle] hyperactivity. Preclinical pharmacological data show that tolterodine exhibits a favourable tissue selectivity in vivo for the urinary

bladder over the effect on the salivation” as compared to oxybutynin. *Id.* at 1:35–43.

A major metabolite of tolterodine, the 5-hydroxymethyl derivative 5-HMT (“5-HMT”), shows in vitro and in vivo pharmacological profiles almost identical to those of tolterodine. *Id.* at 1:49–52 (citing Nilvebrant et al., 1997, *Eur. J. Pharmacol.* 327 (1997), 195–207). “WO 94/1 1337 proposes [5-HMT] as a new drug for urge incontinence.” *Id.* at 1:57–58.

The chemical structures of tolterodine and its active metabolite, 5-HMT (indicated below by “5-HM”), are shown below:



See, e.g., Pet. 8; Ex. 1010, 289; Ex. 1011, 530. As illustrated above, tolterodine has a single hydroxyl group at the 2-position carbon of the methylated phenolic ring, whereas 5-HMT bears a second hydroxyl moiety on the 5-position methyl group of that ring.

C. Illustrative Claim

Claim 1 of the '980 patent is reproduced below:

1. R-(+)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester.

Independent claims 1, 2, 3, 8, and 10 are similarly drawn to compositions, while independent claims 4, 5, and 12 are drawn to methods involving the administration of those compounds.

The composition claims encompass fesoterodine fumarate (R-(+)-2-(3-(diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenylisobutyrate ester

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.